Businessweek

Zeria Pharmaceutical Co., Ltd. manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, and reagents. It also provides cosmetics, health foods, alcoholic beverages, carbonated beverages, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, measuring equipment, and analytical equipment. The company’s primary products comprise ethical pharmaceuticals in the gastrointestinal field, including histamine H2 receptor antagonists, zinc containing anti-ulcerant, ulcerative colitis therapies, oral bowel cleansing agents, anti-inflammatory anti-ulcerants, proton pump inhibitors, and laxatives; and other products consisting of long-acting calcium channel blockers, absorbable topical hemostats, sclerotherapy for leg varicose veins, enzymatic hemostatics, anti-platelet oral jellies, oral non-steroidal anti-inflammatory products, anti-leukopenia after radiotherapies, topical non-steroidal anti-inflammatory products, anti-inflammatory topical blood circulation enhancers, non-steroidal anti-inflammatory ophthalmic solutions, and drugs for hypertension and angina pectoris. Its products also include OTC drugs and products, such as self prevention products, remedies for gastrointestinal diseases, dermal remedies/cosmeceuticals, ophthalmic solutions, cold remedies, nutrient tonics, and topical anti-inflammatory analgesics. The company was founded in 1955 and is headquartered in Tokyo, Japan.